C D40 is a macrophage-expressed costimulatory molecule that interacts with the T cell-expressed CD40L and signals through p38 MAPK and ERK1/2 to differentially regulate IL-10 and IL-12 production (1-3). These two cytokines are major mediators of the immune responses against Leishmania major infection. Whereas CD40-induced p38 MAPK associates with IL-12 production, ERK1/2 activation is associated with IL-10 production (1, 2). In L. major infection, p38 MAPK phosphorylation is impaired, whereas ERK1/2 phosphorylation is enhanced (1, 4) . Such alterations could result from either differential phosphorylation or selective dephosphorylation of these two MAPKs. Although SHP-1, a protein tyrosine phosphatase, has been reported to be upregulated in Leishmania infection and to dephosphorylate MAPKs (5) (6) (7) (8) (9) , the phosphatase has not been shown to exert a selective dephosphorylating activity on p38 MAPK and ERK1/2. Therefore, whether the CD40-induced reciprocal regulation of p38 MAPK and ERK1/2 results from any selective phosphatase functions remains unknown.
Recent reports suggest that MAPK phosphorylation is differentially regulated by dual-specificity MAPK phosphatases (MKPs), which can dephosphorylate both tyrosine and threonine residues on the activated MAPKs and regulate cytokine production (10) (11) (12) . There are 10 such dual-specificity MKPs, which differ in their requirements for substrate and subcellular localization (10) (11) (12) . Among these MKPs, MKP-1 is the most characterized member of the family. MKP-1, primarily a nuclear MKP, shows a significantly higher specificity for p38 MAPK but little specificity for ERK1/2 (13, 14) . MKP-1-deficient mice are more susceptible to septic shock, suggesting that MKP-1 acts as a negative regulator for the induction of inflammatory cytokines such as IL-1b, TNFa, and IL-6 (15, 16) . In contrast, MKP-3 is less characterized and its role in immune response remains unknown. MKP-3 is cytosolic and very specific to ERK1/2 (10) (11) (12) . Additionally, baseline ERK1/2 phosphorylation is enhanced in MKP-3-deficient mice (17) . Thus, these reports imply that MKP-1 and MKP-3 differentially regulate MAPKs, but their selective roles in an immune response remain unknown.
In this study, we show that MKP-1 and MKP-3 are differentially expressed in L. major-infected macrophages. Stimulation of macrophages via CD40 induces reciprocal regulation of the expression and activity of these two MKPs. CD40-induced p38 MAPK and ERK1/2 phosphorylations were significantly altered in the presence of MKP-1 short hairpin RNA (shRNA) and overexpressed MKP-3. Inhibition of MKP-1 expression or overexpression of MKP-3 resulted in decreased L. major infection in a susceptible BALB/c mouse strain. Our data demonstrate the reciprocity between any two MKPs for the first time to our knowledge. The reciprocity between MKP-1 and MKP-3 contributes to the reciprocal CD40 signaling. We also show how the protozoan parasite Leishmania devises a novel MKP-targeted immune evasion strategy. Differential regulation of MKP1 and MKP-3 can redirect CD40 signaling and thereby may regulate many immune responses.
Materials and Methods

Reagents
Triptolide was purchased from Calbiochem (San Diego, CA). Abs specific to MKP-1, MKP-3, p-p38, p38, p-ERK1/2, ERK1/2, and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant IL-10 and anti-IL-10 neutralizing Abs and ELISA Abs (IL-12, IL-10, IFNg, and IL-4) were from BD Biosciences (San Diego, CA).
Mice, parasites, and infection
BALB/c mice and CD40-deficient mice (BALB/c background) were originally obtained from The Jackson Laboratory (Bar Harbor, ME) and were subsequently bred in the experimental animal facility at the National Centre for Cell Science in Thoren caging units (Thoren Caging System, Hazleton, PA). L. major (strain MHOM/Su73/5ASKH) was maintained in vitro in RPMI 1640 medium (Life Technologies-BRL, Grand Island, NY), supplemented with 10% FCS (Life Technologies-BRL), and the virulence was maintained by passage through BALB/c mice. Avirulent or high-passage L. major promastigotes (strain MHOM/Su73/5ASKH) were derived from continuous in vitro culture for .8 y. Avirulent L. major parasites were maintained in vitro in RPMI 1640 medium with 10% FCS and were passaged when the promastigotes reached stationary phase. In experiments with avirulent parasites (high passage), a passage number of .500 was used for infection. Stationary-phase L. major promastigotes (2 3 10 6 ) were used to infect BALB/c mice s.c. in the hind footpad and were treated with triptolide (i.p., 2.5 mg/mouse) or anti-IL-10 Ab (20 mg/ mouse) for 5 d beginning 2 d postinfection. In experiments with lentivirus treatment, mice were injected s.c. in the hind footpad with 5 3 10 6 transduction units of lentivirus-expressing MKP-1 shRNA, control shRNA, MKP-3 wild-type (WT), or control empty vector on day 3 of infection. Some mice were treated with anti-CD40 (i.p., 50 mg/mouse; clone 3/23, a gift from Dr. G. Klaus, London, U.K.) for 3 d alternatively beginning day 4 postinfection. Disease severity was assessed by measurement of footpad swelling using a digital micrometer (Mitutoyo Japan) and parasite burden.
Macrophage culture and L. major infection of macrophages
Thioglycolate-elicited BALB/c-derived peritoneal macrophages were cultured in RPMI 1640 medium, supplemented with 10% FCS. Macrophages were pretreated with different doses of triptolide for 1 h, followed by infection with L. major promastigotes at a ratio of 1:10 for 6 h (1, 4). Extracellular parasites were washed and macrophages were cultured with or without anti-CD40 Ab or anti-IL-10 neutralizing Ab (10 mg/ml) for 60 h and Giemsa stained, followed by counting the number of amastigotes per 100 macrophages. The percentage infectivity in macrophages untreated and L. major-infected was 67-75%.
Quantitative real-time PCR and RT-PCR
RNA was isolated using TRI Reagent (Sigma-Aldrich, St. Louis, MO) and reverse-transcribed using Moloney murine leukemia virus reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA) as described previously (1, 4) . The reactions were performed in thin-wall 0.2-ml strip tubes (Axygen, Union City, CA) in a 10-ml reaction mixture containing 10 ng cDNA, 2 ng forward primer, 2 ng reverse primer, and 23 iQ SYBR Green Supermix (5 ml; Bio-Rad; Hercules, CA). The sequences for the primers used are given in Table I . Quantitative real-time PCR was performed on an Eppendorf realplex 4 Mastercycler under the following conditions: 95˚C for 2 min, 40 cycles of 95˚C for 1 min, 60˚C for 30 s, 72˚C for 35 s. Reactions were performed in duplicates. Relative quantitation was done using the comparative threshold (DDC t ) method. mRNA expression levels of the target genes were normalized against those of GADPH levels and expressed as relative fold change compared with untreated controls. RT-PCR for IL-10, IL-12p40, iNOS2, MKP-1, and GAPDH was performed using the specific primers (Table I) , as described earlier (1, 3, 4) .
Western blotting
Cells were washed twice with chilled PBS and lysed in cell lysis buffer (20 mM Tris [pH 7.4], 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 2 mM EDTA, protease inhibitor mixture [Roche Applied Science, Mannheim, Germany], and phosphates inhibitor mixture [Pierce, Rockford, IL]). Protein was quantified by a BCA kit (Pierce) and an equal amount of protein was run on SDS-PAGE. Resolved proteins were blotted to polyvinylidene difluoride (Millipore, Bedford, MA) and then blocked with 5% nonfat dried milk in TBST (25 mM Tris [pH 7.6], 137 mM NaCl, and 0.2% Tween 20) . Membranes were incubated with primary Ab at 4˚C overnight, washed with TBST, and incubated with HRP-conjugated secondary Ab. Immunoreactive bands were visualized with the Luminol reagent, purchased from Santa Cruz Biotechnology. Densitometric analyses of bands were performed using Quantity One 4.6.1 (basic) software (Bio-Rad).
MKP-1 and MKP-3 immunoprecipitation
Cells were lysed in lysis buffer (20 mM Tris [pH 7.4], 150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 2 mM EDTA, protease inhibitor mixture, and phosphates inhibitor mixture). Equal amounts of proteins were immunoprecipitated using anti-MKP-1 or anti-MKP-3 Abs and collected with protein A/G-agarose (Pierce) beads at 4˚C for 16 h. Immunoprecipitates were washed thee times in cold lysis buffer and subjected to Western blot analysis.
MKP-1 and MKP-3 phosphatase activity assay
Immunoprecipitates of MKP-1 or MKP-3 were washed three times with icecold lysis buffer (20 mM Tris [pH 7.4], 150 mM NaCl, and 1% Nonidet P-40) and phosphatase activity was assayed (18) using a PTP assay kit 2 (Upstate Biotechnology, Lake Placid, NY) according to the manufacturer's protocol. Briefly, immunocomplex pellets were resuspended in p-nitrophenyl phosphate (pNPP) Tyr assay buffer (1 mg/ml BSA, 25 mM HEPES [pH 7.2], 50 mM NaCl, 2.5 mM EDTA, and 10 mM DTT). The reactions were initiated by the addition of pNPP and were performed in duplicate. After incubation for 2 h at 37˚C, absorbance was measured at 410 nm.
Small interfering RNA transfection
The P388D1 macrophage cell line was used to carry out transient transfection studies. MKP-1, MKP-3 and control small interfering RNA (siRNA), transfection medium, and transfection reagent were procured from Santa Cruz Biotechnology. siRNA transfection was carried out according to the manufacturer's protocol. Briefly, 5 3 10 5 cells were plated in 6-well plates 24 h before transfection. siRNA duplex (60 pmol) was used for transfection and cells were transfected in serum-free media. After 6 h, complete medium (1 ml, RPMI 1640 plus 10% FCS) was added; 12 h later, this medium was replaced with standard culture media. After 36 h, cells were stimulated with anti-CD40 and harvested for Western blot or quantitative RT-PCR analysis. Cytokine ELISA Macrophages, either unstimulated or stimulated with CD40 (anti-CD40 Ab; 3 mg/ml), or lymph node cells stimulated with anti-CD3 (0.5 mg/ml) and anti-CD28 (2 mg/ml) Abs for 48 h and culture supernatants were assayed for IL-10/IL-12 or IL-4/IFN-g, respectively, using OptEIA kits (BD Biosciences) as described previously (3).
Production of MKP-1 shRNA and control shRNA lentivirus particles MKP-1 shRNA (GenBank accession no. NM_013642) in pLKO.1 vector and control shRNA carrying scrambled sequence in pLKO.1 was purchased from Open Biosystems (Huntsville, AL). Control shRNA and MKP-1 shRNA were packaged in a Trans-Lentiviral packaging system (replication-incompetent HIV-1-based lentivirus; Open Biosystems) using an HEK293T producer cell line according to the manufacturer's protocol.
Briefly, 5.5 3 10 6 cells were plated in a 100 mm petri plate 1 d before transfection. Trans-Lentiviral packaging mix (28.5 mg) and MKP-1 shRNA (9 mg) or control shRNA (9 mg) plasmid DNA was mixed together. Transfection was carried out in serum-free media using Arrest-In transfection reagent (Open Biosystems) at a 1:5 DNA/transfection reagent ratio. Six hours later medium was changed with standard culture medium (DMEM supplemented with 10% FCS) and cells were incubated for 72 h. Virus supernatant was harvested after 48 and 72 h, combined, and filtered though a 0.45-mm filter (Millipore, Bedford, MA). Virus supernatant was concentrated 100-fold according to the manufacturer's protocol.
Cloning of mouse MKP-3 WT in lentiviral vector pDusp6 SPORT6 (GenBank accession no. BC003869; http://www.uniprot. org/uniprot/Q9DBB1; Open Biosystems) was used as a template for PCR amplification of full-length MKP-3 cDNA using primers sequences the 
In vitro lentiviral transduction
Peritoneal macrophages were transduced with lentiviral particles expressing MKP-1 shRNA, control shRNA, MKP-3 WT, or control empty vector for 8 h in RPMI 1640 supplemented with 0.5% FCS and 8 mg/ml polybrene (Sigma-Aldrich). Cells were washed to remove residual viral particles and 48 h later they were stimulated with anti-CD40 Ab (3 mg/ml) for the indicated times and harvested for Western blot analysis or ELISA.
Statistical analyses
The significance of difference between the means was calculated from a Student t test. The minimum number of mice used for in vivo experiments was five per group. The in vitro cultures were always set in triplicates. The results were plotted as mean 6 SEM.
Results
Leishmania infection reciprocally regulates expression and activity of MKP-1 and MKP-3
Because modulation of expression of the MKPs can in principle be an indicator of their possible involvement in L. major infection, we checked the expression of all MKPs in 72 h L. major-infected macrophages by real-time PCR. Among all nuclear phosphatases, MKP-1 expression was significantly upregulated, whereas of all of the cytosolic phosphatases, MKP-3 expression was most significantly downregulated (Fig. 1A) ; the expression of the nuclear/ cytosolic MKPs remained unaltered (Fig. 1A) . Western blot analyses showed that these phosphatases were reciprocally regulated in macrophages either infected in vitro (Fig. 1B, left panel) or isolated from L. major-infected BALB/c mice (Fig. 1B, right  panel) . These data indicate that MKP-1 and MKP-3 expressions are reciprocally regulated in L. major-infected macrophages.
Next, we studied the kinetics of expressions of MKP-1 and MKP-3 after L. major infection of the thioglycolate-elicited macrophages in vitro. MKP-1 expression was upregulated as early as 1 h postinfection and remained upregulated until 72 h, the endpoint of the kinetics, whereas MKP-3 expression was inhibited completely by 24 h (Fig. 1C) . We also tested whether the activities of MKP-1 and MKP-3 are commensurate with their expressions. We observed that in L. major-infected macrophages, the activity of MKP-1 was enhanced but that of MKP-3 was reduced (Fig.  1D) . Because MKPs are reported to have preferences for MAPKs as substrates (13, 14) , their association with p38 MAPK and ERK1/2 in L. major infection was examined. We observed that MKP-1 was associated with p38 MAPK, whereas MKP-3 was associated with ERK1/2 in L. major-infected macrophages (Fig.  1E) . However, the association of MKP-1 with ERK1/2 and MKP-3 with p38 MAPK was not observed. Because p38 MAPK and ERK1/2 were involved in L. major infection (1-4) , we tested whether the virulent and avirulent strains of L. major would have differential capacity to modulate MKP-1 and MKP-3 expressions. We observed that MKP-1 expression was significantly upregulated by the virulent but not by the avirulent L. major strain (Fig. 1F) . In contrast, the MKP-3 expression was significantly downregulated by the virulent L. major strain but upregulated by its avirulent counterpart (Fig. 1F) . Taken together, these data suggest that MKP-1 and MKP-3 play important roles in L. major infection.
MKP-1 and MKP-3 expression and activity are differentially regulated by CD40
Because CD40 reciprocally modulates the activation of p38 MAPK and ERK1/2, and because MKP-1 and MKP-3 are the phosphatases specific for p38 MAPK and ERK1/2, respectively, we examined whether CD40 regulates the expression of these phosphatases. BALB/c-derived thioglycolate-elicited macrophages were stimulated with the indicated doses of anti-CD40 Ab. The lower dose of anti-CD40 increased MKP-1 expression (Fig. 2A, left panel) , coinciding with suboptimal p38 MAPK activation (Fig. 2B, left  panel) , whereas the high dose of anti-CD40 resulted in diminished MKP-1 expression (Fig. 2A, right panel) , in phase with the enhanced and sustained p38 MAPK phosphorylation (Fig. 2B, right  panel) . In contrast, MKP-3 expression decreased at lower and intermediate doses of anti-CD40 stimulation (Fig. 2A, left and middle panels) and coincided with strong and sustained activation of ERK1/2 (Fig. 2B, left and middle panels) ; at the highest dose of anti-CD40, a steady increase in MKP-3 expression, concurrent with a decline in ERK1/2 activation, was observed ( Fig. 2A, 2B , right panels). These data suggest that CD40 regulates MKP-1 and MKP-3 expression as a function of the strength of stimulation.
Expression of MKP-1 and MKP-3 was compared in uninfected and Leishmania-infected macrophages at different doses of anti-CD40 Ab. Compared to the uninfected macrophages, MKP-1 expression increased but MKP-3 expression decreased in infected macrophages at any dose of anti-CD40 Ab (Fig. 2C) . Next, we assessed the activity of MKP-1 and MKP-3 by pNPP hydrolysis. Increased MKP-1 activity was observed at a lower dose of anti-CD40 Ab in both uninfected and infected macrophages, whereas MKP-1 activity was undetectable in response to a higher dose of anti-CD40 Ab (Fig. 2D) . A reverse profile of CD40-induced MKP-3 activity was observed (Fig. 2D ). These observations further suggest a reciprocal relationship between these phosphatases and CD40-induced p38 MAPK and ERK1/2 phosphorylation.
MKP-1 and MKP-3 reciprocally regulate CD40-induced MAPK phosphorylation and effector functions
To examine whether these dual-specificity phosphatases indeed regulate the CD40-induced p38 MAPK and ERK1/2 phosphorylation and effector functions, we suppressed the expression of MKP-1 and MKP-3 by using specific siRNA. It was observed that reduced MKP-1 expression by its siRNA resulted in enhanced CD40-induced p38 MAPK phosphorylation but reduced ERK1/2 phosphorylation (Fig. 3A) . A reverse effect was observed with MKP-3 siRNA, and MKP-3 inhibition increased ERK1/2 phosphorylation but decreased p38 MAPK phosphorylation (Fig. 3A) . MKP-1 siRNA resulted in increased CD40-induced inducible NO synthase 2 (iNOS2) (Fig. 3B ) and IL-12 ( Fig. 3C) expression, but MKP-3 siRNA increased CD40-induced IL-10 expression (Fig.  3D ) but decreased IL-12 and iNOS2 expression (Fig. 3B, 3C ). Taken together, these results suggest that MKP-1 acts as a negative regulator of CD40-induced proinflammatory cytokine production by inhibiting p38 MAPK phosphorylation. In contrast, by inactivating ERK1/2, MKP-3 negatively regulates CD40-induced antiinflammatory cytokine expression but positively regulates proinflammatory cytokine expression.
Triptolide, an MKP-1 inhibitor, protects susceptible BALB/c mice from L. major infection Because MKP-1 inhibition resulted in CD40-induced increased proinflammatory cytokine expression, we tested whether triptolide, a pharmacological inhibitor of MKP-1 (14, 19) , can recapitulate the siRNA effect in peritoneal macrophages. Consistent with the siRNA results, triptolide treatment led to a dose-dependent inhibition of MKP-1, which correlated with the increased CD40-induced p38 MAPK phosphorylation, IL-12 and iNOS2 expression, whereas it decreased ERK1/2 phosphorylation and IL-10 expression (Fig. 4A, left and right panels) . Because increased iNOS2 and IL-12 expression are hallmarks for anti-leishmanial effects (20, 21) , we tested whether triptolide can prevent parasite multiplication in vitro. We observed that cotreatment of the macrophages with triptolide and anti-CD40 Ab resulted in decreased parasite load and percentage of infectivity in vitro (Fig.  4B) . Triptolide decreases the number of parasites internalized in a dose-dependent manner after 1 h of L. major infection (Fig. 4C) , suggesting that it may also affect the initial uptake of the parasites. We further investigated the anti-leishmanial effect of triptolide on the course L. major infection in susceptible BALB/c mice. Compared to the untreated control mice, those treated with triptolide alone or together with anti-CD40 Ab had less footpad thickness (Fig. 4D, left panel) , diminished lymph node weight (data not shown), and less parasite burden (Fig. 4D, right panel) . Lymph node cells from the infected mice treated with triptolide and anti-CD40 produced significantly higher IFN-g and less IL-4 compared with the cells from untreated infected mice (Fig. 4E) . However, the hostprotective effect of triptolide was abrogated in CD40-deficient mice (Fig. 4F) , suggesting an important role for MKP-1 in the function of CD40 in protection against L. major infection. Anti-IL-10 Ab together with triptolide reduces L. major infection in BALB/c mice Because L. major infection induces the secretion of the proparasitic cytokine IL-10 (22) and upregulates MKP-1 expression, we tested whether IL-10 plays a role in mediating MKP-1 induction. A rIL-10 dose-dependent increase in MKP-1 expression was observed (Fig. 5A, left panel) . However, the treatment of infected macrophages with anti-IL-10 Ab reduced MKP-1 expression by half as compared with untreated infected macrophages (Fig. 5A,  right panel) , suggesting that IL-10 indeed plays a role in the induction of MKP-1 expression in L. major infection. Because MKP-1 expression was not completely abrogated with anti-IL-10 Ab, it is possible that the parasite may directly influence MKP-1 expression. Next, we investigated the effect of anti-IL-10 Ab and MKP-1 inhibition on amastigote multiplication in macrophages. We observed that the cotreatment of macrophages with anti-IL-10 and triptolide significantly reduced the number of amastigotes as well as the percentage of infectivity in vitro (Fig. 5B) . We next examined whether anti-IL-10 Ab treatment can enhance the antileishmanial effect of triptolide in susceptible BALB/c mice. We observed that anti-IL-10 and triptolide alone significantly reduced footpad swelling and parasite burden in L. major-infected BALB/c mice (Fig. 5C, 5D ). Triptolide plus anti-IL-10 cotreatment did not significantly reduce the infection in vivo, suggesting that the inhibition of the MKP-1 phosphatase expression and limiting the inhibitory effects of IL-10 on macrophages may not have a significant synergistic host-protective effect. Therefore, it is plausible that the MKP-1 effect may primarily be mediated through IL-10.
MKP-1 shRNA results in reduced L. major infection
Because triptolide-inhibited MKP-1 expression resulted in less parasite burden in the L. major-infected BALB/c mice, we tested whether lentiviral (Lv)-MKP-1 shRNA also recapitulated the same effect. It was observed that MKP-1 shRNA resulted in less CD40-induced ERK1/2 phosphorylation but higher p38 MAPK phosphorylation (Fig. 6A) . Similarly, Lv-MKP-1 shRNA but not the control shRNA induced higher IL-12 induction but less IL-10 production and reduced parasite burden in vitro by anti-CD40 stimulation (Fig.6B, 6C) , suggesting that the lentiviral expressed MKP-1 shRNA might reduce parasite load in a susceptible host. Indeed, the Lv-MKP-1 shRNA but not the control shRNA significantly enhanced the CD40-induced anti-leishmanial effect in BALB/c mice (Fig. 6D) . The effect of such treatments was not observed in CD40-deficient mice, suggesting the CD40 requirement for the antileishmanial effects exerted by the MKP-1 shRNA (Fig. 6E) .
Taken together, these observations suggest that L. major infection induces IL-10, which at least partially augments MKP-1 expression. As the preferred substrate of MKP-1 is p38 MAPK, it is possible that IL-10-enhanced MKP-1 expression results in increased dephosphorylation of p38 MAPK and less anti-leishmanial functions.
MKP-3 overexpression suppresses L. major infection
Because MKP-3 expression was reduced in L. major-infected macrophages and MKP-3 siRNA enhanced CD40-induced ERK1/ 2 phosphorylation and IL-10 expression, we examined whether MKP-3 overexpression modulates CD40-induced p38 MAPK and (Fig. 7A) . MKP-3 overexpression also increased CD40-induced IL-12 production but less IL-10 production and parasite burden in vitro (Fig. 7B, 7C ). These data suggest that MKP-3 is required for curbing Leishmania growth in macrophages. Indeed, Lv-MKP-3 administration in L. majorinfected BALB/c mice resulted in enhanced CD40-induced parasite clearance (Fig. 7D) . In contrast with the failure of MKP-1 shRNA to reduce parasite load in CD40-deficient mice, MKP-3 overexpression reduced parasite load significantly in CD40-deficient mice (Fig. 7E) , suggesting that in contrast with MKP-1, the MKP-3 effect may not be entirely dependent on CD40 function.
Discussion
The balance between kinases and phosphatases is required for mounting appropriate immune responses against pathogens. Any shift in this equilibrium may result in a dysregulated immune response. We have demonstrated for the first time, to our knowledge, how an intracellular pathogen, L. major, in order to evade the host immune response, exploits intracellular phosphatases MKP-1 and MKP-3 reciprocally to modulate CD40 signaling in its favor. Although these two phosphatases play an important role in the regulation of MAPK signaling (23, 24) , to our knowledge their role together in any signaling pathway has never been addressed. According to our previous proposition, CD40 signaling proceeds by phosphorylation of two reciprocally regulated MAPKs, p38 MAPK and ERK1/2, as a function of the strength of CD40 stimulation (1-3) . The current set of data indicates that the observed reciprocity between ERK1/2 and p38 MAPK may arise due to preferential dephosphorylation, unveiling the crucial function of the MAPK-specific phosphatases in CD40 signaling. L. major preferentially skews the CD40 signaling toward ERK1/2 pathway by upregulation of MKP-1 and downregulation of MKP-3, revealing a novel parasite-employed immune evasion strategy.
The observed association between MKP-1 and p38 MAPK in L. major infection correlates well with the observations made with the MKP-1-deficient mice (13, 16, 25) , which implicate p38 MAPK as the main in vivo substrate for MKP-1. As MKP-1 is a negative regulator of proinflammatory cytokine biosynthesis (13) (14) (15) (16) , the kinetics of L. major infection showed a very early MKP-1 induction, suggesting that to establish infection, the parasite requires MKP-1 functions, perhaps for inhibiting the proinflammatory cytokine synthesis. According to previous reports, the L. major-induced ERK1/2-mediated IL-10 is required for establishment of the infection (26) (27) (28) . In this study, we observed that ERK1/2-specific phosphatase MKP-3 expression was decreased at later stages of the infection, re-emphasizing the host-protective role of MKP-3-mediated ERK1/2 dephosphorylation and implying the association of MKP modulation with the ability of the parasite to establish the infection. Whereas the avirulent parasite decreases MKP-1 induction but increases MKP-3 expression, the virulent parasite exerts an opposite effect of these two MKPs. This corroborates with our observation that CD40-induced p38 MAPK phosphorylation is enhanced, but ERK1/2 phosphorylation is reduced, in avirulent L. major-infected macrophages (N. Srivastava, T.H. Khan, S. Kumari, A. Sareen, R.K. Mathur, A. Chande, R. Mukhopadhyaya, M.V. Krishnasastry, and B. Saha, manuscript in preparation). As the metacyclic form of the parasite is primarily responsible for interaction with macrophages, it is also possible that these virulent and avirulent strains differ in the contents of the metacyclic parasite. Ascertaining the exact mechanism requires a detailed study with isolated forms of the parasite.
So far as the relationship between reciprocal regulations of the phosphatases versus MAPKs is concerned, our data suggest that these phosphatases contribute at least partially to the previously reported reciprocity of MAPKs. We previously showed that CD40-induced p38 MAPK and ERK1/2 pathways are reciprocally regulated such that p38 MAPK inhibition enhances CD40-induced ERK1/2 phosphorylation (1), whereas ERK1/2 inhibition enhances CD40-induced p38 MAPK phosphorylation (Ref. 1 and U. Sarma, A. Sareen, R. Sudan, S. Pahari, N. Srivastava, S. Roy, S. Sinha, I. Ghosh, and B. Saha, manuscript in preparation). Similarly, as TRAF-3 and TRAF-6 are directly related to p38 MAPK and ERK1/2 activation, respectively, silencing of these adaptors also results in reciprocal regulation of the p38 MAPK and ERK1/2 pathways (3). We now know that such reciprocal regulation is due to a minimum of two feedbacks between the terminal MAPK and the initial tyrosine kinases that are recruited to CD40 on the cell membrane (U. Sarma, A. Sareen, R. Sudan, S. Pahari, N. Srivastava, S. Roy, S. Sinha, I. Ghosh, and B. Saha, manuscript in preparation). Because MKP-1 deactivates p38 MAPK, the inhibition of the latter activates ERK1/2 by the principle of reciprocity. Because MKP-3 deactivates ERK1/2, MKP-3 activation enhances p38 MAPK activation.
The CD40 dose-dependent reciprocal MKP-1 and MKP-3 expressions are owing to two mechanisms. Although the synthesis of MKP-1 and MKP-3 may be differentially regulated, these proteins are very labile and are targeted for degradation by the ubiquitindirected proteasome complex (29, 30) . ERK1/2 plays an important role in determining the stability of these proteins. However, the posttranslational modification of MKP-1 and MKP-3 by ERK1/2 has a reverse outcome. ERK1/2-mediated phosphorylation enhances MKP-1 stability and prevents its proteasomal degradation (29) , whereas MKP-3 phosphorylation by ERK1/2 reduces its stability and promotes its degradation (30) . The report is consistent with our observation that a strong CD40 stimulation leads to reduced ERK1/2 phosphorylation, destabilizing MKP-1 and promoting its degradation with concurrent reduction in MKP-3 degradation due to reduced ERK1/2 phosphorylation.
We demonstrate that MKP-3 positively regulates innate immune response such that inhibition of MKP-3 increases CD40-induced IL-10 expression and decreases IL-12 and iNOS2 expression, whereas lentiviral overexpression of MKP-3 enhances CD40-induced IL-12 production and parasite killing but reduces IL-10 production. In contrast, CD40-induced increased expression of iNOS2 and IL-12 is consistent with previous findings that MKP-1-deficient mice challenged with LPS produces higher IL-12 and NO (15, 31) . Collectively, the data suggest that both the phosphatases are reciprocally regulating the immune response in CD40 signaling.
The negative role of MKP-1 in proinflammatory cytokine biosynthesis is well documented. MKP-1-deficient mice challenged with LPS produced substantially greater quantities of proinflammatory molecules such as TNF, IL-6, IL-1b, IL-12p70, iNOS2, MIP-1a, MIP-1b, and MCP-1 (13) (14) (15) (16) . However, it also enhanced greatly the production of the powerful anti-inflammatory cytokine IL-10 (13-16) . Contradictory to what we observed, knock down of MKP-1 by siRNA, Lv-shRNA, or triptolide treatment decreased CD40-induced IL-10 production. Previous reports suggested that LPS-induced IL-10 production is mediated through p38 MAPK activation and to a less extent depend on ERK1/2 or JNK (16) . The apparent differences can be explained by the facts that CD40-induced IL-10 is mediated through ERK1/2 activation (1-3) and also that CD40 signaling reciprocally regulates IL-10 and IL-12 production (1-3) . The triptolide or MKP-1 shRNA or siRNA enhanced CD40-induced IL-12 production whereas anti-IL-10 Ab suppressed MKP-1 expression in infected macrophages. These data corroborate one another. First, MKP-1 inhibition by siRNA (Fig. 3D) or shRNA (Fig. 6B) inhibits CD40-induced IL-10 expression, suggesting that MKP-1 is directly associated with IL-10 production. Similarly, triptolide, which inhibits MKP-1 expression, also decreases IL-10 expression (Fig. 4A) . Third, anti-IL-10 Ab reduces MKP-1 expression in infected macrophages (Fig. 5A) . Finally, rIL-10 enhances MKP-1 expression in a dose-dependent manner (Fig. 5A) . We know from our previous studies that CD40-induced IL-10 expression is mediated through ERK1/2 activation (1, 3) . In this study, we show that MKP-1 silencing decreases ERK1/2 phosphorylation, which results in decreased IL-10 expression. Thus, MKP-1 is related to IL-10 via ERK1/2 activation, which may result from MKP-1-mediated p38 MAPK dephosphorylation, as ERK1/2 and p38 MAPK are reciprocally regulated.
That L. major reciprocally regulates MKP-1 and MKP-3 in vivo is further indicated by the significantly reduced L. major infection in the BALB/c mice treated with Lv-MKP-1 shRNA or triptolide or Lv-MKP-3 overexpression together with anti-CD40 Ab. The possibility for the use of available MKP-1 KO mice was ruled out by the fact that the genetic background of those MKP-1 KO mice was on the L. major-resistant C57/129 mixed background (13, FIGURE 8. The proposed model for the reciprocal regulation of CD40 signaling in L. major in infection by MKP-1 and MKP-3. A higher dose of anti-CD40 Ab preferentially activates p38 MAPK to induce proinflammatory cytokine IL-12 and iNOS2, resulting in reduced parasite multiplication and host protection. In contrast, lower doses of anti-CD40 stimulation preferentially activate ERK1/2, inducing anti-inflammatory cytokine IL-10; this results in disease progression. The reciprocity between p38 MAPK and ERK1/2 phosphorylation was earlier thought to be entirely due to differential phosphorylation of these MAPKs. In this study, we show that differential activation of two phosphatases, MKP-1 and MKP-3, can also lead to the reciprocity between the MAPKs. A higher dose of anti-CD40 Ab stimulation inhibits MKP-1 expression but enhances MKP-3 expression, whereas lower doses of anti-CD40 Ab stimulation have a reverse effect. Because MKP-1 preferentially dephosphorylates p38 MAPK, MKP-1 inhibition results in host protection through enhanced IL-12 and NO production. In contrast, because MKP-3 preferentially dephosphorylates ERK1/2, MKP-3 overexpression results in host protection. As a survival strategy, L. major upregulates MKP-1 but downregulates MKP-3 expressions, skewing CD40 signaling toward ERK1/2 activation and IL-10 production. 32, 33) . Reduced MKP-1 expression in anti-IL-10 Ab-treated L. major-infected macrophages is consistent with the IL-10-induced MKP-1 expression in activated macrophages (34) , suggesting an important role for MKP-1 in the anti-inflammatory function of IL-10. Furthermore, in many tumors, MKP-1 expression is upregulated (35, 36) and is associated with cisplatin resistance (37) . In contrast, MKP-3 acts as a tumor suppressor in several cancer models (38) (39) (40) . All of these observations indicate reciprocity between these two phosphatases, which is schematically presented in Fig. 8 .
Our observations on the reciprocal regulation of MKP-1 and MKP-3 expressions in L. major infection are contradictory to the previously reported upregulation of both MKP-1 and MKP-3 in Leishmania donovani infection (41) . The same report has shown a general suppression of both ERK1/2 and p38 MAPK in L. donovani infection, as opposed to reciprocal modulation of these two MAPKs in L. major infection. Thus, the overall association between ERK1/2 and MKP-3 or p38 MAPK and MKP-1 holds true, and the apparent difference between the previous report and ours is due to difference in the species of Leishmania used for infection. Interestingly, as MKP-1 is a nuclear phosphatase and MKP-3 is a cytosolic phosphatase, no direct association between these two phosphatases is indicated. It is possible that the reciprocity may arise from the feedback modulation of the MAPKs they dephosphorylate. However, this proposition remains to be tested.
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